Clinuvel Pharmaceuticals Limited (AU:CUV)
ASX:CUV
Want to see AU:CUV full AI Analyst Report?
Top Page
Clinuvel Pharmaceuticals
(Sydney:CUV)
Select Model
Select Model
Rating:72Outperform
Price Target:
AU$10.00
▼(-9.75% Downside)
Action:Reiterated
Date:04/03/26
Score is driven primarily by strong financial performance (profitability, cash generation, and a debt-free balance sheet). This is tempered by weak technical momentum with the stock trading below key moving averages and a negative MACD. Valuation appears reasonable, while the earnings call was constructive on cash strength and catalysts but flagged meaningful expense increases and timing/regulatory risks.
Positive Factors
Strong balance sheet
A large cash position and two decades operating without debt give durable financial flexibility. Low leverage reduces refinancing and solvency risk, enabling self-funding of clinical programs, manufacturing scale-up and commercial expansion without reliance on dilutive or costly external financing.
Negative Factors
Rising operating expenses
Material expense growth—personnel, commercial distribution and R&D consumables—raises structural operating leverage. If revenue growth remains modest, sustained expense escalation can compress margins, increase cash burn volatility and reduce the pace at which investments translate into profitable scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
A large cash position and two decades operating without debt give durable financial flexibility. Low leverage reduces refinancing and solvency risk, enabling self-funding of clinical programs, manufacturing scale-up and commercial expansion without reliance on dilutive or costly external financing.
Read all positive factors
Clinuvel Pharmaceuticals (CUV) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$453.85M
Dividend Yield0.38%
Average Volume (3M)97.23K
Price to Earnings (P/E)13.6
Beta (1Y)0.64
Revenue Growth5.17%
EPS Growth-16.14%
CountryAU
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.65
Shares Outstanding50,427,900
10 Day Avg. Volume118,433
30 Day Avg. Volume97,231
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.16
Price to Sales (P/S)5.47
P/FCF Ratio12.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$28.10Price Target Upside153.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.72
Revenue Forecast (FY)AU$99.22M
Clinuvel Pharmaceuticals Business Overview & Revenue Model
Company Description
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with severe skin disorders and other related conditions. The company operates primarily in the healthcare s...
How the Company Makes Money
Clinuvel primarily makes money from sales of its commercial product SCENESSE (afamelanotide). Revenue is generated when SCENESSE is supplied to healthcare providers/centers and reimbursed through applicable payment pathways in the markets where it...
Clinuvel Pharmaceuticals Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Sep 01, 2026
Earnings Call Sentiment Positive
The call conveys a generally positive outlook driven by modest revenue growth, record first-half sales, strong cash reserves and sustained profitability while management deliberately invests in in-house R&D, clinical and manufacturing capabilities. Those positives are tempered by materially higher operating expenses across personnel, R&D and corporate areas, a non-cash FX translation loss, and timing/uncertainty around regulatory filings (CUV107 completion required before submission) and the NASDAQ ADR uplift. On balance, the company emphasizes that expense increases are strategic investments supported by a strong balance sheet and cash runway.Positive Updates
Revenue Growth and Record First-Half Sales
Sales revenue increased 4% year-on-year to just under $37 million, marking the company's highest-ever first-half sales and continuing a steady growth pattern.
Negative Updates
Overall Expense Growth
Total expenses increased 22% for the period, driven by the company’s expansion initiatives and higher operating activity, resulting in lower net profit relative to prior periods.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue Growth and Record First-Half Sales
Sales revenue increased 4% year-on-year to just under $37 million, marking the company's highest-ever first-half sales and continuing a steady growth pattern.
Read all positive updates
Company Guidance
Guidance from the call was that CLINUVEL will continue a controlled expansion while tightly managing costs, with full‑year operating expense guidance of about A$55–58m (ex‑capex); H1 sales rose 4% YoY to just under A$37m (the highest H1 on record), interest income was A$5.3m (up 14%), cash increased by A$9m to A$233m, net assets rose A$8.2m to ~A$250m, the company remains debt‑free for a 21st year and has delivered its 20th consecutive profit. Management flagged expense drivers (total expenses +22%: personnel +16%, commercial distribution +42%, finance/legal +47%, other R&D +191%), lower non‑cash and share‑based charges (share plan now 1‑year), term deposits average ~300 days at ~4.5% yield, revenue split ~53% U.S./47% RoW, <5% U.S. patients on Medicaid, and near‑term catalysts include CUV105 topline in H2 2026, start of CUV107, peptide preclinical data H2 2026 and the ADR/NASDAQ uplift pending SEC responses.Clinuvel Pharmaceuticals Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
80
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 96.30M | 95.02M | 88.18M | 78.32M | 65.72M | 47.98M |
| Gross Profit | 61.36M | 79.14M | 80.45M | 50.59M | 46.62M | 35.20M |
| EBITDA | 41.65M | 57.20M | 56.28M | 46.37M | 35.08M | 28.19M |
| Net Income | 32.54M | 36.17M | 35.64M | 30.60M | 20.88M | 24.73M |
Balance Sheet | ||||||
| Total Assets | 269.70M | 271.75M | 231.12M | 194.52M | 144.81M | 108.57M |
| Cash, Cash Equivalents and Short-Term Investments | 233.00M | 224.11M | 183.87M | 156.81M | 121.51M | 82.69M |
| Total Debt | 341.09K | 528.53K | 879.78K | 999.87K | 1.26M | 1.30M |
| Total Liabilities | 20.68M | 30.94M | 28.11M | 29.89M | 19.25M | 9.83M |
| Stockholders Equity | 249.02M | 240.81M | 203.01M | 164.63M | 125.56M | 98.74M |
Cash Flow | ||||||
| Free Cash Flow | 40.08M | 40.80M | 31.48M | 35.88M | 39.44M | 18.41M |
| Operating Cash Flow | 40.47M | 41.10M | 37.05M | 36.91M | 39.87M | 19.26M |
| Investing Cash Flow | -18.64M | -47.72M | -29.03M | -1.03M | -434.44K | -854.33K |
| Financing Cash Flow | -2.71M | -2.94M | -3.57M | -2.24M | -1.50M | -1.48M |
Clinuvel Pharmaceuticals Technical Analysis
Negative
11.08
Price Trends
9.25
Negative
10.15
Negative
10.97
Negative
Market Momentum
-0.10
Positive
41.28
Neutral
54.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CUV, the sentiment is Negative. The current price of 11.08 is above the 20-day moving average (MA) of 9.19, above the 50-day MA of 9.25, and above the 200-day MA of 10.97, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 41.28 is Neutral, neither overbought nor oversold. The STOCH value of 54.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CUV.
Clinuvel Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$453.85M | 13.65 | 13.29% | 0.38% | 5.17% | -16.14% | |
53 Neutral | AU$51.30M | 61.12 | 17.85% | ― | 38.44% | 230.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$1.30B | -16.14 | -30.03% | ― | ― | 22.52% | |
47 Neutral | AU$317.80M | -96.59 | -15.96% | ― | 364.97% | 74.50% | |
45 Neutral | AU$57.42M | -0.49 | -131.13% | ― | 2086.71% | -116.20% | |
43 Neutral | AU$6.79M | -2.27 | -211.88% | ― | 250.37% | 71.29% |
* Healthcare Sector Average
AU:CUV
Clinuvel Pharmaceuticals
8.83
-1.52
-14.68%
AU:ACR
Acrux
0.01
-0.01
-45.83%
AU:SPL
Starpharma Holdings Limited
0.75
0.66
697.87%
AU:PYC
PYC Therapeutics Limited
1.28
0.09
7.96%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.30
-93.12%
AU:BIO
Biome Australia Ltd
0.27
-0.20
-42.55%
Clinuvel Pharmaceuticals Corporate Events
Clinuvel Leverages AAD 2026 to Advance Vitiligo, EPP Strategy and U.S. Profile
Apr 2, 2026
Clinuvel used the 2026 American Academy of Dermatology Annual Meeting in Denver to highlight progress in its vitiligo and erythropoietic protoporphyria (EPP) programs, centering on its melanocortin drug afamelanotide. Case studies from the CUV105 ...
Clinuvel Showcases AI Vitiligo Tool and EPP Therapy at Major U.S. Dermatology Meeting
Mar 26, 2026
Clinuvel Pharmaceuticals is showcasing its melanocortin-based programs at the 2026 American Academy of Dermatology Meeting in Denver, highlighting SCENESSE for erythropoietic protoporphyria and its development work in vitiligo. The company is posi...
Clinuvel Backs CEO Wolgen as Cash-Rich Biotech Prioritises Vitiligo Push
Mar 19, 2026
Clinuvel Pharmaceuticals reported its strongest first-half financial performance, maintaining profitability despite higher planned expenses and ending 31 December with A$233 million in cash, giving it substantial strategic flexibility. The board h...
Clinuvel Profit Dips on Higher Expansion Costs Despite Record Half-Year Revenue
Feb 26, 2026
Clinuvel Pharmaceuticals reported a 4% rise in half-year revenues to A$36.9 million, driven by increased commercial and Special Access Scheme sales of its flagship drug SCENESSE for erythropoietic protoporphyria and higher interest income on large...
Clinuvel Flags Wide-Ranging Risks Ahead of Institutional Investor Meetings
Feb 1, 2026
Clinuvel Pharmaceuticals has issued an update noting its ongoing clinical and financial activities ahead of institutional investor meetings hosted by Jefferies, while emphasizing the inherent uncertainty in its forward-looking statements. The comp...
Clinuvel Starts Preclinical Dosing of New Controlled-Release Peptide Platform VLRX-L
Jan 11, 2026
Clinuvel Pharmaceuticals has begun dosing in a new preclinical study of VLRX-L, its in-house developed controlled-release liquid injectable peptide platform designed to deliver melanocortin-based and other peptide drugs with reproducible release p...
Clinuvel Reports New Positive Vitiligo Data for SCENESSE® in Darker-Skinned Patients
Jan 7, 2026
Clinuvel Pharmaceuticals has reported new clinical data from four Fitzpatrick VI (darker skin type) adult patients enrolled in its ongoing CUV105 study evaluating SCENESSE® in vitiligo, presented at the Regional Dermatology Training Center co...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.